Friday 6 November 2026 Export EXEL’s income statement to Excel — free account

Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.

Revenue: +10.2%
EPS: +22.2%
Free cash flow: −4.83%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

69.84 1.13 +1.64%

Follow EXEL

Alert me

Market cap: $16.8B
P/E: 19.9×
Fwd P/E: 20.2×
Dividend yield: —
F-score: 7/9
Altman Z: 12.68
Beneish M: −2.61
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Exelixis, Inc. (EXEL) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Exelixis, Inc. (EXEL) trades at a price to free cash flow of 14.8×. Over the past ten years it has ranged from 0.0× (March 2016) to 64.7× (January 2018); the current reading is higher than 31% of that period. That is below the Biotechnology industry median of 24.8× and below the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/EXEL/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Exelixis, Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/EXEL/metrics/price-to-free-cash-flow">Exelixis, Inc. (EXEL) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	14.1×	(7.49%)
FY2024	15.2×	(65.90%)
FY2023	44.7×	91.15%
FY2022	23.4×	36.71%
FY2021	17.1×	(50.62%)
FY2020	34.6×	233.98%
FY2019	10.4×	(32.26%)
FY2018	15.3×	(75.98%)
FY2017	63.7×	260.63%
FY2016	17.7×	—

Period	Price to free cash flow	Change
Sep 2026	12.6×	6.88%
Jun 2026	11.8×	(3.74%)
Mar 2026	12.2×	(13.17%)
Dec 2025	14.1×	(5.36%)
43 more quarters	Free account

Against its own ten years

Low 0.0× High 64.7×

Ten-year median 19.3×

Current reading's percentile 31

Company	Price to free cash flow
SMMT Summit Therapeutics PLC compare	n/m
BNTX BioNTech SE Sponsored ADR compare	n/m
BBIO BridgeBio Pharma, Inc. compare	n/m
INSM Insmed, Inc. compare	n/m
EXEL Exelixis, Inc.	14.8×
HALO Halozyme Therapeutics, Inc. compare	15.9×
JAZZ Jazz Pharmaceuticals PLC compare	22.2×
ALNY Alnylam Pharmaceuticals, Inc. compare	26.1×
ASND Ascendis Pharma A/S compare	42.1×
Biotechnology industry median	24.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Exelixis, Inc. (EXEL) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on EXEL

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on EXEL

Stockrow Weekly